Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
about
Protein kinase CK2 and human malignant tumorsOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.Identification and characterization of a novel testis-specific gene CKT2, which encodes a substrate for protein kinase CK2Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.Peptide-based vaccines for cancer: realizing their potential.Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.Casein kinase: the triple meaning of a misnomer.Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.Casein kinases as potential therapeutic targets.The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell linesSensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.A FRET-based microplate assay for human protein kinase CK2, a target in neoplastic disease.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Q27026335-ABA80B75-A241-492B-B079-2E7F044D81BEQ27332192-FAA7A0DB-DF2D-421C-AEDE-9E5A789039C3Q28509081-FD8C275C-632D-4699-855C-F06399BE9192Q34122676-F203F0F8-C36E-491B-ACD0-7B0F7FA1A18AQ34247901-39FD7436-0F5C-403C-9927-73F4F8D98F11Q34265716-94A78287-44BF-4A0C-A7E4-39D7C7C053B5Q34342416-50532E79-44DD-486A-8A9F-F6DF1AD513B0Q37340462-9799E0D7-9F9E-4DCD-AE98-DD7E80B855E6Q37487082-3C6181F9-9FCA-4A7D-8D6F-9D19CD915E35Q38211598-D78EDE18-86E4-4D19-A646-A7F7941E833FQ38365378-23C9F6FD-602A-4338-8E4F-D3D2C5ADCB71Q38557670-955E4416-010C-4D0C-8C39-A5D4E9E34B68Q38632634-3C7D90BF-A15E-408B-8419-861767A4F68EQ38709045-24E8B3D6-F93E-4958-86BF-403A13E72FD8Q39381625-B5254A04-C2B6-4B57-AE80-6849CE2E2006Q43252750-861910C0-4E98-4550-B1B0-4C151E3B3797Q47677919-2A8F6EF9-8E3B-4830-BDDF-8BF7B5F98328
P2860
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Systemic administration of a p ...... es solid tumor growth in mice.
@en
type
label
Systemic administration of a p ...... es solid tumor growth in mice.
@en
prefLabel
Systemic administration of a p ...... es solid tumor growth in mice.
@en
P2093
P356
P1476
Systemic administration of a p ...... ces solid tumor growth in mice
@en
P2093
Boris E Acevedo
Daniel E Gómez
Hernán G Farina
Ignacio Hernández
Joem M Serrano
Osmany Mendoza
Osvaldo Reyes
Roberto E Gómez
Silvio E Perea
Yasser Perera
P356
10.1002/IJC.23013
P577
2008-01-01T00:00:00Z